Infectious Disease Molecular Diagnostics Market Size, Share and Global Trend By Technology (Mass Spectroscopy, Capillary Electrophoresis, Next Generation Sequencing, Chips & Microarrays, In-Situ Hybridization), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV) Infection, Human Papillomavirus (HPV) Infection), By End User (Hospitals & Clinics, Diagnostic Centres, Research Institutes) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Infectious diseases refer to the diseases caused by various organisms such as bacteria, virus, parasites, and fungi and can be passed from individual to individual or even from animal to individuals such as rabies. Early and accurate detection of infectious diseases is of utmost importance as it spread from one person to another. Molecular diagnostics serve as an effective tool for the detection of HIV, HPV, and other infectious diseases.
There is active support from the government to tackle the rising prevalence and economic burden of infectious diseases. Also, strategic collaboration and the launch of new molecular diagnostic platforms or instruments have surged the market. Awareness and shift towards personalized medicines and preventive care are expected to further enhance the demand for infectious disease diagnostic techniques.
To gain extensive insights into the market, Request for Customization
The global infectious disease molecular diagnostics market is anticipated to grow owing to the increasing prevalence of infectious diseases, rising awareness regarding prevention and early diagnosis of sexually transmitted diseases, and active government support. The World Health Organization (WHO) estimated that there were approximately 36.9 million individuals diagnosed with HIV at the end of 2017, with a new 1.8 million people diagnosed in 2017 globally. These trends, combined with the other factors, are expected to drive the growth in the infectious disease molecular diagnostics market growth during the forecast duration.
However, lack of skilled labor in developing countries, high installation and infrastructure cost can hinder the growth in the global infectious disease molecular diagnostics market.
Key Players Covered
Some of the major companies that are present in the global infectious disease molecular diagnostics market are Abbott, Becton, Dickinson and Company, QIAGEN, Cepheid, bioMérieux SA, Hologic Inc., Myriad Genetics and Thermo Fisher Scientific.
SEGMENTATION
SEGMENTATION | DETAILS |
By Technology | · Mass Spectroscopy · Capillary Electrophoresis · Next Generation Sequencing (NGS) · Chips & Microarrays · In-Situ Hybridization (ISH) · Others |
By Disease Indication | · Hepatitis · Human Immunodeficiency Virus (HIV) Infection · Human Papillomavirus (HPV) Infection · Others |
By End User | · Hospitals & Clinics · Diagnostic Centres · Research Institutes · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Among the segmentation, Next Generation Sequencing (NGS) segment is projected to hold a considerable share of the global infectious disease molecular diagnostics market in the forecast period due to increased preference for next-generation sequencing technology, new product launch, increased research and cost-effectiveness.
Key Insights
- Prevalence of infectious diseases
- The regulatory scenario for key countries
- Reimbursement scenario for key countries
- New product launch
- Technological advancements in molecular diagnosis
- Recent industry developments such as partnerships, mergers, and acquisitions
Regional Analysis
North America is estimated to dominate the global infectious disease molecular diagnostics market over the forecast period due to the increasing prevalence of infectious diseases such as HIV and respiratory diseases, established healthcare system, and increased R&D investment. Asia Pacific is projected to report significant growth in the global infectious disease molecular diagnostics market due to active government support, improving access to the advanced diagnostic facility and rapid adoption of preventive care.
Key Industry Developments
- In August 2018, Bruker Corporation announced the acquisition of Hain Lifescience GmbH, an infectious disease molecular diagnostic company, to expand their footprint in molecular diagnostics.
- In January 2019, Qiagen announced the launch of QIAscreen HPV PCR Test, an in-vitro molecular diagnostics test for the detection of human papillomavirus in Europe.
- In February 2018, BD received per-marketing approval from the FDA for the BD Onclarity HPV assay to be performed on molecular platform using BD Viper LT system to identify human papillomavirus (HPV) genotypes.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
